The treatment has gained approval in the European Union (EU) for a range of conditions, including psoriatic arthritis, ...

JAK inhibitor Rinvoq (upadacitinib) has been backed by the CHMP as a 15mg, once-daily treatment for adults with GCA, an ...

Ariel Investments, an investment management company, released its “Ariel Global Fund” fourth-quarter 2024 investor letter. A ...

Right now, Rinvoq is approved in the European Union and the U.S. for the treatment of adults with radiographic axial ...

Crain’s health care reporter Katherine Davis joins host Amy Guth to talk about the latest news from around the industry.

Rinvoq (upadacitinib) is not safe to take while pregnant or breastfeeding. Certain factors, such as the form of Rinvoq you’re prescribed, may determine whether you should take the drug during ...

EMA committee recommends approval of AbbVie’s upadacitinib to treat adults with giant cell arteritis: North Chicago, Illinois Monday, March 3, 2025, 15:00 Hrs [IST] AbbVie annou ...

Stock market investors have enjoyed strong annual returns over the past two years, but analysts caution that 2025 may not ...

RINVOQ is approved in the European Union (EU) for the treatment of adults with radiographic axial spondylarthritis, nonradiographic axial spondylarthritis, psoriatic arthritis, rheumatoid ...

AbbVie said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended expanded approval of its blockbuster autoimmune drug Rinvoq for the treatment of adults with ...

Eli Lilly and Company, UnitedHealth Group, AbbVie, Walmart, Johnson & Johnson, Natera, and Gilead Sciences are the seven Medical stocks to watch today, according to MarketBeat’s stock screener tool.